{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for aminosalicylic root_protein_modifications_structuralModifications_molecularFragment_refPname in Protein Structural Modification Substance Name (approximate match)
Status:
US Approved Rx
(2017)
Source:
BLA761040
(2017)
Source URL:
First approved in 2017
Source:
BLA761040
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2016)
Source:
BLA125521
(2016)
Source URL:
First approved in 2016
Source:
BLA125521
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2014)
Source:
BLA125514
(2014)
Source URL:
First approved in 2014
Source:
BLA125514
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2015)
Source:
BLA125527
(2015)
Source URL:
First approved in 2014
Source:
BLA125554
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2017)
Source:
BLA761043
(2017)
Source URL:
First approved in 2011
Source:
BLA125370
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2011)
Source:
BLA125399
(2011)
Source URL:
First approved in 2011
Source:
BLA125399
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2013)
Source:
BLA125472
(2013)
Source URL:
First approved in 2010
Source:
BLA125276
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2009)
Source:
BLA125289
(2009)
Source URL:
First approved in 2009
Source:
BLA125289
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2007)
Source:
BLA125166
(2007)
Source URL:
First approved in 2007
Source:
BLA125166
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2000)
Source:
NDA020715
(2000)
Source URL:
First approved in 2000
Source:
NDA020715
Source URL:
Class:
PROTEIN
Conditions:
Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). It works by decreasing the production of certain hormones, which reduces testosterone levels in the body. Animal studies comparing triptorelin to native GnRH found that triptorelin had 13 fold higher releasing activity for luteinizing hormone, and 21-fold higher releasing activity for follicle-stimulating hormone. Triptorelin is indicated for the palliative treatment of advanced prostate cancer.